New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis

Dennis Zavalloni, Mauro De Benedictis, Paolo Pagnotta, Innocenzo Scrocca, Patrizia Presbitero

Research output: Contribution to journalArticlepeer-review


The treatment of degenerated surgical bio-prosthetic heart valves (BHV) has been reported as a novel indication for TAVI. The intervention may be complicated by high residual transvalvular gradients and coronary ostia obstruction, especially in small size BHV. We report two cases of BHVs treated with the new CoreValve Evolut 23. mm highlighting the importance of fluoroscopic guidance, based on BHV markers, in achieving a correct TAVI implantation. The small dimensions of the new CoreValve Evolut 23 allowed us to obtain low residual gradients even in this particular subset of degenerated BHV.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalHeart Lung and Circulation
Issue number2
Publication statusPublished - Feb 2014


  • Aortic stenosis
  • Aortic valve replacement
  • Bioprosthesis degeneration
  • Interventional cardiology
  • TAVI

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'New CoreValve Evolut 23mm Technology for Treatment of Degenerated Bioprosthesis'. Together they form a unique fingerprint.

Cite this